Last reviewed · How we verify
TLK286 in combination with docetaxel — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
TLK286 in combination with docetaxel (TLK286 in combination with docetaxel) — Telik.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| TLK286 in combination with docetaxel TARGET | TLK286 in combination with docetaxel | Telik | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- TLK286 in combination with docetaxel CI watch — RSS
- TLK286 in combination with docetaxel CI watch — Atom
- TLK286 in combination with docetaxel CI watch — JSON
- TLK286 in combination with docetaxel alone — RSS
Cite this brief
Drug Landscape (2026). TLK286 in combination with docetaxel — Competitive Intelligence Brief. https://druglandscape.com/ci/tlk286-in-combination-with-docetaxel. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab